Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

1.2.1.36: retinal dehydrogenase

This is an abbreviated version!
For detailed information about retinal dehydrogenase, go to the full flat file.

Word Map on EC 1.2.1.36

Reaction

retinal
+
NAD+
 +
H2O
=
retinoate
 +
NADH
 +
H+

Synonyms

aldehyde dehydrogenase 1, aldehyde dehydrogenase 1A1, aldehyde dehydrogenase 1A2, aldehyde dehydrogenase 1A3, ALDH 1A1, ALDH 1A2, ALDH class 1, ALDH-1A1, ALDH-3A1, ALDH1, ALDH1A1, Aldh1a2, Aldh1a3, BcALDH, cytosolic retinal dehydrogenase, dehydrogenase, retinal, dehydrogenase/reductase member 3, DHRS3, ETA-crystallin, More, NAD+-dependent aldehyde dehydrogenase, NAD-dependent retinal dehydrogenase, NAD-dependent retinal dehydrogenases, PB-RALDH, phenobarbital-induced aldehyde dehydrogenase, RALDH, RALDH-1, RALDH-3, RalDH1, RALDH1A1, RALDH2, RALDH3, Raldh4, RDH12, RDH13, RDH5, retialdehyde dehydrogenase, Retinal dehydrogenase, retinal dehydrogenase 1, retinal dehydrogenase 2, retinal dehydrogenase 3, retinal dehydrogenase 4, retinal dehydrogenase 5, retinal dehydrogenase type-2, retinal dehydrogenase-2, retinal dehydrogenase/reductase, retinal short-chain dehydrogenase/reductase, retinalaldehyde dehydrogenase 2, retinaldehyde dehydrogenase, retinaldehyde dehydrogenase 1, retinaldehyde dehydrogenase 2, retinaldehyde dehydrogenase 3, retinaldehyde dehydrogenase type II, retinaldehyde dehydrogenase type-1, retinaldehyde dehydrogenase-2, retinaldehyde dehydrogenases, retinol dehydrogenase 13, retSDR1, testis-specific aldehyde dehydrogenase, thyroid-hormone-binding protein, type 2 retinaldehyde dehydrogenase, xCTBP, xCTBP/xALDH1, zRalDH

ECTree

     1 Oxidoreductases
         1.2 Acting on the aldehyde or oxo group of donors
             1.2.1 With NAD+ or NADP+ as acceptor
                1.2.1.36 retinal dehydrogenase

Inhibitors

Inhibitors on EC 1.2.1.36 - retinal dehydrogenase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
1-(6-fluoro-3-(4-(methylsulfonyl)piperazine-1-carbonyl)-quinolin-4-yl)-4-phenylpiperidine-4-carbonitrile
i.e. NCT-505
-
2,3,5,6,9-pentamethyl-7H-furo[3,2-g][1]benzopyran-7-one
21.6% inhibition at 0.01 mM
-
2,3,5,6-tetramethyl-7H-furo[3,2-g][1]benzopyran-7-one
9.5% inhibition at 0.01 mM
-
2,3,5-trimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
63.7% inhibition at 0.01 mM
-
2,3,5-trimethyl-6-[3-oxo-3-(piperidin-1-yl)propyl]-7H-furo[3,2-g][1]benzopyran-7-one
91.3% inhibition at 0.01 mM
-
2,3-dimethyl-5-propyl-7H-furo[3,2-g][1]benzopyran-7-one
25.9% inhibition at 0.01 mM
-
2-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
16.79% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
14.47% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
29.37% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
8.5% inhibition at 0.01 mM at pH 7.5, 25°C
-
2-Iodoacetamide
-
slight
2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]-N-phenylacetamide
50.4% inhibition at 0.01 mM
-
2-[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetamide
71.5% inhibition at 0.01 mM
-
2H-furo[2,3-h][1]benzopyran-2-one
39.0% inhibition at 0.01 mM
-
3,3',5-tri-iodothyronine
-
3,3',5-Triiodothyroacetic acid
-
0.001 mM, 60% inhibition
3,4,10-trimethyl-2H,6H-benzo[1,2-b:5,4-b']dipyran-2,6-dione
32.6% inhibition at 0.01 mM
-
3,4,8,9-tetramethyl-7H-furo[2,3-f][1]benzopyran-7-one
38.5% inhibition at 0.01 mM
-
3,4-dimethyl-6,7,8,9-tetrahydro-2H-[1]benzofuro[3,2-g][1]benzopyran-2-one
35.7% inhibition at 0.01 mM
-
3,5-dimethyl-6-propyl-7H-furo[3,2-g][1]benzopyran-7-one
51.4% inhibition at 0.01 mM
-
3-(4-(4-(trifluoromethyl)benzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
3.86 % inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-bromobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
24.42% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-chlorobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
37.43% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-cyanobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
24.52% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
68.27% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-fluorobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
31.19% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
77.15% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
60.51% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
47.31% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(4-nitrobenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
28.33% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(cyclopropanecarbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
0.05% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-(furan-2-carbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
9.44% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-benzoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
39.23% inhibition at 0.01 mM at pH 7.5, 25°C at pH 7.5, 25°C
-
3-(4-isonicotinoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
36.65% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(4-nicotinoylpiperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
30.95% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-(benzo[d][1,3]dioxole-5-carbonyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)propanamide
35.93% inhibition at 0.01 mM at pH 7.5, 25°C
-
3-benzyl-4-methyl-2-oxo-2H-1-benzopyran-7-yl methanesulfonate
75.4% inhibition at 0.01 mM
-
3-tert-butyl-5,6-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
5.5% inhibition at 0.01 mM
-
3-[(3-oxobutan-2-yl)oxy]-6H-dibenzo[b,d]pyran-6-one
41.3% inhibition at 0.01 mM
-
3-[4-(furan-2-carbonyl)piperazin-1-yl]-N-(3-methylbut-2-en-1-yl)-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)propanamide
-
-
4-(1,3-dihydro-2H-isoindol-2-yl)benzaldehyde
-
-
4-(4-(4-ethylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
27.23% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-isopropylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
33.01% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-methoxybenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
13.10% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-(4-(4-methylbenzoyl)piperazin-1-yl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-N-(3-methylbut-2-en-1-yl)acetamide
32.19% inhibition at 0.01 mM at pH 7.5, 25°C
-
4-biphenyl carboxylic acid
-
90% inhibition at 0.1 mM in cell culture in vivo, leads to posterolateral defects in the diaphragm in vivo
4-diethylaminobenzaldehyde
-
partial inhibition
4-dimethylamino-4-methyl-pent-2-ynthioic acid S-methyl ester
-
-
4-methyl-7-(2-oxo-2-phenylethoxy)-2H-1-benzopyran-2-one
71.0% inhibition at 0.01 mM
-
4-methyl-7-(2-oxopropoxy)-2H-1-benzopyran-2-one
47.8% inhibition at 0.01 mM
-
4-methyl-7-[(3-methylbut-2-en-1-yl)oxy]-2H-1-benzopyran-2-one
61.7% inhibition at 0.01 mM
-
4-methyl-7-[(prop-2-en-1-yl)oxy]-2H-1-benzopyran-2-one
64.5% inhibition at 0.01 mM
-
5-benzyl-2,3-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
43.0% inhibition at 0.01 mM
-
5-methyl-2-[(3-oxobutan-2-yl)oxy]-7H-furo[3,2-g][1]benzopyran-7-one
31.3% inhibition at 0.01 mM
-
6-benzyl-3,5-dimethyl-7H-furo[3,2-g][1]benzopyran-7-one
12.6% inhibition at 0.01 mM; 41.5% inhibition at 0.01 mM
-
6-bromo-3-[(1E)-N-hydroxyethanimidoyl]-2H-1-benzopyran-2-one
-
-
6-methyl-3,4-dihydro-2H,8H-benzo[1,2-b:5,4-b']dipyran-2,8-dione
34.8% inhibition at 0.01 mM
-
7-(2-oxopropoxy)-2H-1-benzopyran-2-one
7.6% inhibition at 0.01 mM
-
7-(diethylamino)-4-methyl-2H-1-benzopyran-2-one
85.7% inhibition at 0.01 mM
-
7-methoxy-4-methyl-2H-1-benzopyran-2-one
19.8% inhibition at 0.01 mM
-
8,9-dimethyl-2,3-dihydrocyclopenta[c]furo[3,2-g][1]benzopyran-4(1H)-one
49.2% inhibition at 0.01 mM
-
8-[[4-(3-furoyl)-1-piperazinyl]methyl]-1,3-dimethyl-7-(3-methylbutyl)-3,7-dihydro-1H-purine-2,6-dione
i.e. CM026, 75.22% inhibition at 0.01 mM at pH 7.5, 25°C at pH 7.5, 25°C
-
9,10-dimethyl-1,2,3,4-tetrahydro-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
43.7% inhibition at 0.01 mM
-
9,10-dimethyl-5H-6,8-dioxacyclopenta[b]phenanthren-5-one
17.6% inhibition at 0.01 mM
-
acetaldehyde
all-trans-retinal
-
9-cis-retinoic acid synthesis from 0.002 mM 9-cis-retinal is inhibited 50% by 0.005 mM all-trans-retinal
all-trans-retinol
-
competitive
alpha,alpha'-dipyridyl
-
slight
apo-CRBP
-
IC50 0.0014 mM
-
Atabrine
-
slight, FAD reverses inhibition
beta-ionone
potent inhibitor of isoform RALDH4 activity, at 0.002 mM concentration 9-cis and 13-cis retinal oxidation is reduced by 53% and 63%, respectively
Ca2+
-
50% inhibition at 0.22 mM
Chloral hydrate
citral
D-3,3',5-triiodothyronine
-
0.001 mM, 65% inhibition
dichloro-all-trans-retinone
-
diethylaminobenzaldehyde
DEAB, an ALDH1A1 inhibitor which competitively binds to the aldehyde-binding pocket of ALDH1A1 and completely inhibits the aldehyde oxidation activity of the enzyme at 0.01 mM, but has no effect on the GSH/DHLA-dependent NAD+-reduction activity
dimethyl ampal thiolester
-
Disulfiram
estrogen
downregulates Raldh1 expression in the uterine glandular epithelium
ethanol
-
competitive inhibition
ethyl ([4-oxo-3-[3-(pyrrolidin-1-yl)propyl]-3,4-dihydro[1]benzothieno[3,2-d]pyrimidin-2-yl]sulfanyl)acetate
i.e. CM37
-
L-thyroxine
-
0.001 mM, 64% inhibition
Mn2+
-
50% inhibition at 0.024 mM
N,N'-(octane-1,8-diyl)bis(2,2-dichloroacetamide)
WIN 18,446; WIN 18,446, strong irreversible inhibition; WIN 18,446, weak inhibition
-
N,N'-octamethylenebis (dichloroacetamide)
-
complete inhibition at very low concentration below 1 pM in cell culture in vivo, leads to posterolateral defects in the diaphragm in vivo
N,N-diethylaminobenzaldehyde
-
N-(2-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-methoxybenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(2-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3,5-dimethylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-(trifluoromethyl)benzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
6.25% inhibition at 0.01 mM at pH 7.5, 25°C
-
N-(3-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-methoxybenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(3-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4,7-dimethyl-2-oxo-2H-1-benzopyran-6-yl)-2-methylpropanamide
40.2% inhibition at 0.01 mM
-
N-(4-chlorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4-fluorobenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(4-methylbenzyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclobutylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclohexylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclopentylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-(cyclopropylmethyl)-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-benzyl-3-(2,3,5-trimethyl-7-oxo-7H-furo[3,2-g][1]benzopyran-6-yl)propanamide
6.4% inhibition at 0.01 mM
-
N-benzyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-butyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-ethyl-3-[4-(furan-2-carbonyl)piperazin-1-yl]-N-(4-methyl-2-oxo-2H-1-benzopyran-7-yl)propanamide
-
-
N-ethyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isobutyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isopentyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-isopropyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
N-propyl-N-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3-(4-(4-isopropylbenzoyl)piperazin-1-yl)propanamide
-
-
NADPH
-
0.2 mM, 79% inhibition
nitrofen
-
90% inhibition at 0.1 mM in cell culture in vivo, leads to posterolateral defects in the diaphragm in vivo
p-chloromercuribenzoate
-
-
p-hydroxymercuribenzoate
-
complete inhibition at 1 mM in absence of DTT, 2 mM DTT protect nearly completely; strongly suppress enzyme reaction, reversed by addition of DTT
pravastatin sodium
-
cholesterol-lowering agent downregulates the expression of RALDH1,2 genes
retinal
retinol
-
40% uncompetitive inhibition of all-trans-retinal oxidation at 0.012 mM
SB-210661
-
80% inhibition at 1 mM in cell culture in vivo, leads to posterolateral defects in the diaphragm in vivo
WIN 18446
-
Zn2+
-
50% inhibition at 0.01 mM
[(4-methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]acetonitrile
64.3% inhibition at 0.01 mM
-
[(5E)-2,4-dioxo-5-([4-[(4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)methoxy]phenyl]methylidene)-1,3-thiazolidin-3-yl]acetic acid
a 2,4-thiazolidinedione-3-acetic acid derivative
-
[3-benzyl-5-(4-chlorophenyl)-1-oxopyrimido[4,5-c]quinolin-2(1H)-yl]acetic acid
a 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivative; a 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivative and a non-competitive inhibitor of ALDH1A3
-
additional information
-